Quick Answer
bioAffinity Technologies, Inc. reported Total Revenue of $6.16 million for fiscal year 2025.
bioAffinity Technologies, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.16M -34.2% |
$9.36M +269.7% |
$2.53M +52627.4% |
$4.8K | — | — |
| Revenue (ASC 606) | $6.16M -34.2% |
$9.36M +269.7% |
$2.53M +52627.4% |
$4.8K | — | — |
| Net Income | -$14.91M -64.9% |
-$9.04M -13.9% |
-$7.94M +2.7% |
-$8.15M -28.9% |
-$6.33M | — |
| Diluted EPS | -$8.66 +61.5% |
-$22.50 -2372.5% |
-$0.91 +49.7% |
-$1.81 | — | — |
| Total Assets | $10.96M +68.3% |
$6.51M -20.8% |
$8.22M -32.5% |
$12.18M +738.2% |
$1.45M | — |
| Cash and Equivalents | $6.45M +483.5% |
$1.11M -60.8% |
$2.82M -75.3% |
$11.41M +738.9% |
$1.36M | — |
| Stockholders Equity | $7.28M +179.7% |
$2.60M -46.4% |
$4.86M -56.0% |
$11.04M +169.9% |
-$15.79M -4.8% |
-$15.07M |
| R&D Expense | $1.38M -5.3% |
$1.46M -0.5% |
$1.47M +6.5% |
$1.38M +36.8% |
$1.01M | — |
| Operating Income | -$10.57M -18.1% |
-$8.95M -12.3% |
-$7.97M -98.8% |
-$4.01M -81.8% |
-$2.21M | — |
| Gross Profit | — | — | — | $4.3K | — | — |
| Shares Outstanding | 4.50M +766.5% |
519,158 -94.5% |
9.39M +12.1% |
8.38M +213.1% |
2.68M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.45M | -38.5% | +13.9% |
| Revenue (ASC 606) | September 30, 2025 | $1.45M | -38.5% | +13.9% |
| Net Income | September 30, 2025 | -$5.05M | -152.4% | -24.4% |
| Diluted EPS | September 30, 2025 | -$4.74 | +2.1% | -2688.2% |
| Total Assets | September 30, 2025 | $11.55M | +76.2% | +143.0% |
| Cash and Equivalents | September 30, 2025 | $7.67M | +913.7% | +855.3% |
| Stockholders Equity | September 30, 2025 | $8.90M | +185.2% | +516.7% |
| R&D Expense | September 30, 2025 | $330.6K | +20.4% | +6.2% |
| Operating Income | September 30, 2025 | -$2.29M | -16.2% | +8.9% |
| Gross Profit | September 30, 2023 | $223.8K | +22188.8% | +1109.4% |
| Shares Outstanding | September 30, 2025 | 3.47M | -74.2% | -87.8% |
- bioAffinity Technologies, Inc. reported Total Revenue of $6.16 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed a decrease of -34.2% in Total Revenue compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Revenue (ASC 606) of $6.16 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed a decrease of -34.2% in Revenue (ASC 606) compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Net Income of -$14.91 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed a decrease of -64.9% in Net Income compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Diluted EPS of $8.66 per share (loss) for fiscal year 2025.
- bioAffinity Technologies, Inc. showed an increase of +61.5% in Diluted EPS compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Total Assets of $10.96 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed an increase of +68.3% in Total Assets compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Cash and Equivalents of $6.45 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed an increase of +483.5% in Cash and Equivalents compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Stockholders Equity of $7.28 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed an increase of +179.7% in Stockholders Equity compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported R&D Expense of $1.38 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed a decrease of -5.3% in R&D Expense compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Operating Income of -$10.57 million for fiscal year 2025.
- bioAffinity Technologies, Inc. showed a decrease of -18.1% in Operating Income compared to the prior fiscal year.
- bioAffinity Technologies, Inc. reported Gross Profit of $4.3 thousand for fiscal year 2022.
- bioAffinity Technologies, Inc. reported Shares Outstanding of 4.50 million shares for fiscal year 2025.
- bioAffinity Technologies, Inc. showed an increase of +766.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: